Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Harliku Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Harliku Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of Harliku 2 mg tablets for alkaptonuria under the Boeing commercial formulary, including prior authorization, prerequisite-agent, specialist, contraindication, renewal, and quantity-limit requirements.

    Policy Summary
    PayerPrime Therapeutics
    PolicyHarliku Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date08-01-2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting alkaptonuria, including a qualifying clinical finding and confirmatory urine HGA testing or HGD genetic testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 mgHarliku tablet strength
    30 tabletsProgram quantity limit
    12 monthsApproval duration
    2Prerequisite agents

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Alkaptonuria
    Covered indication

    Coverage Criteria

    Initial Therapy

    Target Agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • Diagnosis of alkaptonuria evidenced by BOTH of the following

      • ONE or more clinical findings

        • Family history of alkaptonuria
        • Dark/black urine
        • Arthritis of the spine and/or larger joints
        • Hypothyroidism
        • Calcification (e.g., heart valves, intervertebral discs, or coronary artery)
        • Renal stones
        • Prostate stones
        • Ochronosis (e.g., bluish-black or brown pigmentation of connective tissue such as tendons, ear cartilage, and sclerae)
        • Discolored cerumen
        • Discolored perspiration
      • ONE of the following laboratory findings; medical records required

        • A 24-hour urine sample confirming greater than or equal to 1 gram of homogentisic acid (HGA)
        • A genetic test confirming mutations on the homogentisate 1,2 dioxygenase (HGD) gene
    • If the patient has an FDA-labeled indication, ONE of the following

      • The patient's age is within FDA labeling for the requested indication for the requested agent
      • There is support for using the requested agent for the patient's age for the requested indication
    • ONE of the following; medical records required

      • Tried and had an inadequate response to TWO prerequisite agents (nitisinone capsule and Nityr tablet) that is not expected to occur with the requested agent
      • Tried and had an inadequate response to ONE prerequisite agent and had an intolerance or hypersensitivity to ONE prerequisite agent that is not expected to occur with the requested agent
      • An intolerance or hypersensitivity to TWO prerequisite agents that is not expected to occur with the requested agent
      • An FDA-labeled contraindication to ALL prerequisite agents that is not expected to occur with the requested agent
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist or rheumatologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis
    • The patient does NOT have any FDA-labeled contraindications to the requested agent

    Renewal Therapy

    Target Agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process

      Patients not previously approved for the requested agent will require initial evaluation review.

    • The patient has had clinical benefit with the requested agent as indicated by a reduction in urinary homogentisic acid

      Medical records required.

    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist or rheumatologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis
    • The patient does NOT have any FDA-labeled contraindications to the requested agent

    Quantity-Limit Approval

    Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met:

    ANY of the following

    • A

      • The requested quantity does not exceed the labeled dose for the requested indication
      • The requested quantity does not exceed the program quantity limit
    • B

      • The requested quantity exceeds the labeled dose for the requested indication
      • There is support for the requested quantity for the requested indication

    The requested quantity (dose) is supported by ONE of the following

    Coverage excludes patients with any FDA-labeled contraindication to Harliku (the requested agent).

    Coding and Quantity Details

    Diagnostic thresholdA 24-hour urine sample must confirm greater than or equal to 1 gram of homogentisic acid (HGA).
    Program quantity limit30 tablets for Harliku 2 mg tablets.

    Provider Actions and Decision Risks

    Prior Authorization

    Initial Prior Authorization Required

    Initial prior authorization is required for the target agent. Initial approval requires documentation that the patient meets the alkaptonuria diagnostic criteria, any applicable FDA age or indication requirements, prerequisite-agent pathway, specialist involvement, and absence of FDA-labeled contraindications to the requested agent.

    • Submit medical records supporting all applicable initial-approval criteria.
    • If the patient has an FDA-labeled indication, document that the patient's age is within FDA labeling or provide support for use at the patient's age for the requested indication.
    • Initial approval length is subject to the program criteria and applicable quantity-limit requirements.
    Prior Authorization

    Renewal Prior Authorization

    Renewal prior authorization is required for continued treatment. Renewal approval requires prior approval through the plan's prior authorization process and documented clinical benefit, in addition to ongoing specialist involvement and no FDA-labeled contraindication to the requested agent.

    Condition Background

    Alkaptonuria is associated with accumulation of homogentisic acid (HGA). Clinical manifestations may include dark or black urine, ochronosis with bluish-black or brown pigmentation of connective tissues, degenerative arthritis, calcification, renal or prostate stones, discolored cerumen, and discolored perspiration. Urinary HGA testing or genetic testing for mutations in the HGD gene may support diagnosis; reduction in urinary HGA is used to assess clinical benefit during renewal.

    Definitions

    DefinitionHomogentisic acid (HGA) is measured in urine to support diagnosis of alkaptonuria.
    Diagnostic roleA 24-hour urine sample confirming greater than or equal to 1 gram of HGA is a qualifying confirmatory test.
    Renewal roleA reduction in urinary HGA is used to demonstrate clinical benefit for renewal.
    Full nameHomogentisate 1,2 dioxygenase gene.
    RelevanceGenetic testing confirming mutations on the HGD gene may confirm alkaptonuria.
    DocumentationMedical records are required for the genetic confirmation used in the diagnostic criteria.

    Initial Therapy

    Initial Therapy

    Initial approval requires ALL of the following.

    Harliku initial therapy

    • Documented alkaptonuria

      • ONE or more qualifying clinical findings

        • Family history of alkaptonuria; dark or black urine; arthritis of the spine or larger joints; hypothyroidism; calcification such as heart-valve, intervertebral-disc, or coronary-artery calcification; renal stones; prostate stones; ochronosis; discolored cerumen; or discolored perspiration.
      • ONE confirmatory test

        • A 24-hour urine sample confirms greater than or equal to 1 gram of homogentisic acid (HGA).>= 1 gram HGA in a 24-hour urine sample

    Continuation Therapy

    Continuation Therapy

    Renewal approval requires ALL of the following.

    Harliku continuation therapy

    • The patient was previously approved for Harliku through the plan's prior authorization process.
    • The patient has had clinical benefit with Harliku, demonstrated by a reduction in urinary homogentisic acid.Reduction in urinary homogentisic acid

      Medical records required for benefit documentation.

    • Specialist involvement

      • The prescriber is a specialist in the area of the patient's diagnosis, such as a geneticist or rheumatologist.

    Step-Therapy Requirements

    StepPrerequisite agent(s)Requirement or exception
    1Nitisinone capsule and Nityr tabletThe patient tried both agents and had an inadequate response that is not expected with Harliku.
    Alternative pathwayNitisinone capsule and Nityr tabletThe patient tried one agent and had an inadequate response, and had intolerance or hypersensitivity to the other agent that is not expected with Harliku.
    Alternative pathwayNitisinone capsule and Nityr tabletThe patient had intolerance or hypersensitivity to both agents that is not expected with Harliku.
    Alternative pathwayNitisinone capsule and Nityr tabletThe patient has an FDA-labeled contraindication to both agents that is not expected with Harliku.

    Quantity Limits

    MedicationHarliku (nitisinone) 2 mg tablets.
    Program quantity limit30 tablets per day supply duration.
    Policy Summary
    PayerPrime Therapeutics
    PolicyHarliku Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date08-01-2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting alkaptonuria, including a qualifying clinical finding and confirmatory urine HGA testing or HGD genetic testing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Quantity DetailsProvider Actions and Decision RisksCondition BackgroundDefinitionsInitial TherapyContinuation TherapyStep-Therapy RequirementsQuantity Limits
    • ALL of the following

      • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication
      • There is support for therapy with a higher dose for the requested indication
    • ALL of the following

      • The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication
      • There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit
    • Patients not previously approved through the plan's prior authorization process require initial-evaluation review.
    • Renewal approval requires medical records documenting a reduction in urinary homogentisic acid.
    • The prescriber must be a specialist in the area of the diagnosis, such as a geneticist or rheumatologist, or must have consulted with such a specialist.
    • The patient must not have any FDA-labeled contraindications to the requested agent.
    Step Therapy

    Prerequisite-Agent Pathway

    The patient must satisfy the prerequisite-agent pathway before initial approval. Document the applicable trial, failure, intolerance, hypersensitivity, or contraindication pathway for nitisinone capsule and/or Nityr tablet.

    • Tried and had an inadequate response to both prerequisite agents, where the inadequate response is not expected to occur with the requested agent; or
    • Tried and had an inadequate response to one prerequisite agent and had intolerance or hypersensitivity to the other, not expected to occur with the requested agent; or
    • Had intolerance or hypersensitivity to both prerequisite agents, not expected to occur with the requested agent; or
    • Has an FDA-labeled contraindication to all prerequisite agents, not expected to occur with the requested agent.
    Documentation Required

    Alkaptonuria Diagnostic Documentation

    Document the diagnosis of alkaptonuria in the medical record. Approval requires at least one specified clinical finding and confirmatory urine or genetic testing.

    • Document one or more clinical findings: family history of alkaptonuria; dark or black urine; arthritis of the spine or larger joints; hypothyroidism; calcification such as of heart valves, intervertebral discs, or coronary arteries; renal stones; prostate stones; ochronosis; discolored cerumen; or discolored perspiration.
    • Provide either a 24-hour urine sample confirming ≥ 1 gram of homogentisic acid (HGA) or genetic testing confirming mutations in the homogentisate 1,2 dioxygenase (HGD) gene.
    • Medical records are required for the confirmatory urine or genetic documentation.
    Documentation Required

    Prerequisite-Agent History

    Document the patient's history with the prerequisite agents and explain why the response or adverse experience is not expected with the requested agent.

    • Identify the prerequisite agent(s): nitisinone capsule and/or Nityr tablet.
    • Document inadequate response, intolerance, hypersensitivity, or an FDA-labeled contraindication, as applicable.
    • For inadequate response, document trials of the required number of prerequisite agents and why the inadequate response is not expected with the requested agent.
    • For intolerance, hypersensitivity, or contraindication, document that the issue is not expected to occur with the requested agent.

    Unsupported block type: documentation

    Denial Risk

    Insufficient Diagnosis Confirmation

    Approval may be denied when alkaptonuria is not adequately confirmed. A clinical suspicion or isolated finding is insufficient without the required confirmatory documentation.

    • Do not omit documentation of at least one qualifying clinical finding.
    • Provide either a 24-hour urine result showing ≥ 1 gram HGA or genetic confirmation of HGD mutations.
    • Missing, conflicting, or insufficient urine or genetic confirmation creates a diagnosis-confirmation denial risk.
    Denial Risk

    Step-Therapy Requirements Not Met

    Approval may be denied when the required prerequisite-agent pathway is not met or is not documented. The request must establish the applicable trials and outcomes involving nitisinone capsule and/or Nityr tablet.

    • Document the required two inadequate-response trials, or the combination of one inadequate-response trial plus one intolerance or hypersensitivity, as applicable.
    • Alternatively, document intolerance or hypersensitivity to both prerequisite agents, or FDA-labeled contraindications to all prerequisite agents.
    • Explain why each documented inadequate response, intolerance, hypersensitivity, or contraindication is not expected with the requested agent.
    Denial Risk

    Specialist or Contraindication Requirement Not Met

    Approval may be denied when specialist involvement or the requested-agent safety requirements are not established.

    • The prescriber must be a specialist in the area of the patient's diagnosis, such as a geneticist or rheumatologist, or must document consultation with such a specialist.
    • Document that the patient has no FDA-labeled contraindications to the requested agent.
    • Failure to document either the specialist requirement or the absence of contraindications creates a denial risk.
    Denial Risk

    Renewal Criteria Not Met

    Renewal may be denied when the patient was not previously approved through the plan's prior authorization process or when continued clinical benefit is not documented.

    • Patients without prior plan approval require initial-evaluation review rather than renewal review.
    • Submit medical records showing a reduction in urinary homogentisic acid with the requested agent.
    • Also maintain documentation of specialist involvement and no FDA-labeled contraindication to the requested agent.
    Denial Risk

    Quantity-Limit Criteria Not Met

    Quantity-limit approval requires support for the requested indication and dose or quantity under the program's FDA-label and quantity-limit rules.

    • Document the requested indication and the applicable labeled dose or program quantity limit.
    • A quantity exceeding the usual limit requires that the requested agent have no maximum FDA-labeled dose for the indication and that therapy at the higher dose is supported.
    • If the requested quantity does not exceed the maximum FDA-labeled dose, document why the quantity cannot be achieved with a lower quantity of a higher strength that remains within the program quantity limit.
    • Requests lacking FDA-label, program-limit, or supporting documentation may be denied.
    • Quantity-limit approval is issued for 12 months.
    DefinitionAlkaptonuria is a condition associated with qualifying clinical findings and confirmation by urinary HGA testing or HGD genetic testing.
    Clinical findingsQualifying findings include family history, dark or black urine, arthritis of the spine or larger joints, hypothyroidism, calcification, renal or prostate stones, ochronosis, discolored cerumen, or discolored perspiration.
    Confirmation methodsConfirmation requires either a 24-hour urine sample showing greater than or equal to 1 gram of HGA or genetic testing confirming mutations on the HGD gene.

    Medical records required.

  1. Genetic testing confirms mutations on the homogentisate 1,2 dioxygenase (HGD) gene.

    Medical records required.

  2. Applicable FDA age requirement

    • The patient's age is within FDA labeling for the requested indication.
    • There is support for using Harliku for the patient's age and requested indication.
  3. Prerequisite-agent requirement

    • The patient tried and had an inadequate response to two prerequisite agents—nitisinone capsule and Nityr tablet—and the inadequate response is not expected to occur with Harliku.
    • The patient tried and had an inadequate response to one prerequisite agent and had intolerance or hypersensitivity to another, and the intolerance or hypersensitivity is not expected to occur with Harliku.
    • The patient had intolerance or hypersensitivity to two prerequisite agents, and the intolerance or hypersensitivity is not expected to occur with Harliku.
    • The patient has an FDA-labeled contraindication to all prerequisite agents, and the contraindication is not expected to occur with Harliku.
  4. Specialist involvement

    • The prescriber is a specialist in the area of the patient's diagnosis, such as a geneticist or rheumatologist.
    • The prescriber has consulted with a specialist in the area of the patient's diagnosis.
  5. No contraindication

    • The patient does not have any FDA-labeled contraindications to Harliku.
  6. The prescriber has consulted with a specialist in the area of the patient's diagnosis.
  7. No contraindication

    • The patient does not have any FDA-labeled contraindications to Harliku.